Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$31.49 USD
-0.18 (-0.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $31.48 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AGIO 31.49 -0.18(-0.57%)
Will AGIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGIO
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
Other News for AGIO
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report